Ambergen

Ambergen is a pioneer in next-generation spatial biology, leveraging its proprietary Miralys™ photocleavable mass-tag technology to significantly enhance the capabilities of mass spectrometry imaging (MSI). Founded in 2000 with roots in photonic technology from Boston University, the company has evolved from developing basic research reagents to offering a full suite of products (probes, panels, kits) and laboratory services for ultra-high-plex, multiomic tissue analysis. With a strategic minority investment from Bruker and a focus on enabling drug development and complex disease research, Ambergen is positioned at the convergence of proteomics, diagnostics, and spatial biology.

Miralys™ Photocleavable Mass-Tag Imaging platform for highly multiplexed, multiomic mass spectrometry imaging (MSI). Uses antibody-bound photocleavable tags released by UV laser to enable simultaneous spatial mapping of 150+ proteins alongside native small molecules, lipids, and glycans from a single tissue sample.

Ambergen competes in the spatial proteomics segment against platform companies like Standard BioTools (GeoMx Protein), Akoya Biosciences (CODEX/PhenoCycler), and Lunaphore. Its MSI-based approach differentiates it by offering higher plex potential and direct multiomic capability on a mass spectrometer, but it faces competition from these more established, non-MS imaging modalities that may have simpler workflows.